1. Balukova E. V., Uspenskiy Yu.P., Fominykh Yu. A. Liver diseases of various genesis (toxic, drug-induced, dys-metabolic): from etiological heterogenicity to a single unified therapy of patients. RMJ. Medical Review. 2018. no. 1(I), pp. 35-40.
2. Hagstrom, Н. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of hepatology. 2017. Vol. 67, no. 6, pp. 1265-1273.
3. Long Wang, Jinghui Guo, Jianping Lu. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females. Oncotarget. 2016. Vol. 7, no. 24, pp. 35632-35642.
4. Bedogni, G. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006. no. 6, pp. 33.
5. Bedossa P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease / P. Bedossa. Hepatology. 2014. Vol. 60, pp. 565-575.